Ameera Shah-led Metropolis Healthcare, a pathology laboratory chain, hosted a scientific symposium on genomics, bringing together over 300 clinicians, researchers, scientists and academicians to advance the clinical integration of genomic diagnostics across India’s healthcare ecosystem.
The symposium also marked the formal unveiling of Metropolis’ Centre of Genomics to the clinician community, reinforcing the Company’s broader clinical engagement initiative focused on embedding advanced molecular diagnostics into routine medical practice. As precision medicine gains momentum in India and globally, the forum highlighted the shift from episodic testing to integrated, molecular-driven care pathways enabling earlier diagnosis, precise risk stratification, and personalised treatment across oncology, neurology, and women & child health.
Across oncology, discussions centred on tumour profiling, biomarker-driven therapies, and the expanding role of next-generation sequencing in guiding targeted cancer care. Neurogenomics sessions examined inherited and rare neurological disorders, including genetic epilepsies and neuromuscular conditions, highlighting how genomic testing can reduce diagnostic delays and enable personalised management strategies. In women and child health, experts explored reproductive genomics, prenatal diagnostics, and genetic counselling, underscoring the role of early molecular insights in improving pregnancy outcomes and paediatric care.
These thematic discussions were conducted through parallel sub-specialty sessions led by key opinion leaders, medical advisory board members, and distinguished national and international speakers, featuring panel discussions and case-based deliberations to deepen clinical engagement across specialties.
Clinicians also shared real-world case experiences demonstrating how genomics is enabling a transition from symptomatic management to evidence-based, targeted interventions, improving diagnostic clarity and reducing uncertainty in complex clinical scenarios. The discussions reflected a broader shift toward longitudinal, data-driven diagnostic journeys that support continuous and personalised patient management.
Commenting on the initiative, Ameera Shah, promoter and executive chairperson, Metropolis Healthcare, said, “The next phase of healthcare will be defined by how effectively genomic intelligence is embedded into clinical workflows at scale. The opportunity ahead lies in creating connected ecosystems where diagnostics, data science, and clinical expertise work seamlessly together. At Metropolis, we are focused on integrating molecular intelligence into everyday decision-making so that precision medicine moves toward becoming the standard of care, not the exception.”
Dr. Kirti Chadha, chief scientific and innovation officer, Metropolis Healthcare, said, “As genomic medicine expands, the real challenge is not access to technology but ensuring accuracy, interpretation, and accountability at every step. Scaling responsibly requires rigorous validation frameworks, structured reporting standards, and close collaboration between scientists and clinicians so that genomic findings are applied with clarity and confidence in patient care.”
